Exenatide
Exenatide (GLP-1 receptor agonist)
Also known as: Byetta, Bydureon
The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class.
Overview
Exenatide is derived from exendin-4, a protein in Gila monster saliva. Resistant to DPP-4 degradation, it became the first FDA-approved GLP-1 agonist in 2005. Its twice-daily and once-weekly formulations proved the concept of durable GLP-1 agonism and enabled the later development of liraglutide, semaglutide, and tirzepatide.
Mechanism of action
Agonizes the GLP-1 receptor with roughly 53% homology to human GLP-1, enhancing insulin secretion, reducing glucagon, and slowing gastric emptying.
Key studies & citations
- Human2005
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
336 patients at 82 US sites: HbA1c fell 0.78% (10 mcg twice daily) and 0.40% (5 mcg) versus a 0.08% rise on placebo, with dose-dependent weight loss of up to 2.8 kg.
Diabetes Care - In vitro1992
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom
Original isolation of the 39-amino-acid exendin-4 from Gila monster (Heloderma suspectum) venom, the molecule on which exenatide is based.
Journal of Biological Chemistry - Human2017
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL)
14,752 patients, median 3.2 years: MACE in 11.4% on weekly exenatide vs 12.2% on placebo (HR 0.91, 95% CI 0.83 to 1.00), noninferior for safety but not statistically superior.
New England Journal of Medicine
Frequently asked questions
Is exenatide really from a lizard?
Yes. It is based on exendin-4, a peptide found in Gila monster saliva, which is naturally resistant to the enzyme that degrades human GLP-1.